169.44 USD
▼-3.56-2.06%
盘后 169.07 -0.22%
2026-09-15
市值
$6.82B
市盈率
—
EPS
-2.74
股息率
—
52 周区间
64.80 – 200.00
成交量
151.85K
Beta
-1.24
目标价
228.89
52W 低 64.8052W 高 200.00
价格走势
公司简介
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical dev...